Targets › RIPK1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2028.
Serine-threonine kinase which is a key regulator of TNF-mediated apoptosis, necroptosis and inflammatory pathways. Exhibits kinase activity-dependent functions that regulate cell death (apoptosis and necroptosis) and kinase-independent scaffold functions regulating inflammatory signaling and cell survival. (UniProt, Q13546)
Open in Phaseline: the race on RIPK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gustave Roussy, Cancer Campus, Grand Paris | TOLINAPANT (ASTX660) RIPK1 inhibitor | RIPK1 | Phase 1 | Locally-advanced Rectal Cancer | Jan 2028 |
Locally-advanced Rectal Cancer (1)
small molecule (1)
Gustave Roussy, Cancer Campus, Grand Paris (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.